Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study

  • Cristiana Ferreira Serviço de Imunoalergologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • Ana Oliveira Serviço de Dermatologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • Antonia Furtado Serviço de Anatomia Patológica, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • Natividade Rocha Serviço de Dermatologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • Jose Almeida Ribeiro Serviço de Medicina Interna, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

Keywords

rivaroxaban, bullous pemphigoid-like, cutaneous drug eruptions

Abstract

Little has been documented about hypersensitivity reactions caused by treatment with rivaroxaban. This paper reports a bullous pemphigoid-like skin eruption that occurred in a 76-year-old female patient during rivaroxaban treatment. This case highlights the vigilance required by healthcare workers in recognising potential adverse effects of newly marketed drugs and in making medication changes when necessary. A bullous pemphigoid-like eruption due to treatment with rivaroxaban has not, to the best of the Authors’ knowledge, been reported previously in the literature.

VIEW THE ENTIRE ARTICLE

References

Lowell A. Goldsmith, Stephen I. Katz, Barbara A. Gilchrest, Amy S. Paller, David J. Leffell, Klaus Wolff. Fitzpatrick's Dermatology in General Medicine, 8e. McGraw-Hill Companies, 2012.

Lee A, Thomson J. Adverse Drug Reactions. 2nd ed. London: Pharmaceutical Press; 2006. Drug-induced skin reactions. In: Lee A, editor; pp. 126–55.

Ma HJ, Hu R, Jia CY, Yang Y, Song LJ. Case of drug-induced bullous pemphigoid by levofloxacin. J Dermatol. 2012;39(12):1086–87.

Duong TA, Buffard V, André C, Ortonne N, Revuz J, Bagot M, et al. Efalizumab induced bullous pemphigoid. J Am Acad Dermatol. 2010;62:161–62.

Karadag AS, Bilgili SG, Calka O, Onder S, Kosem M, Burakgazi-Dalkilic E. A case of levetiracetam induced bullous pemphigoid. Cutan Ocul Toxicol. 2013;32(2):176–78.

Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases. Diabetes Care. 2011;34:e133.

Sehgal VN, Khandpur S, Sardana K, Bajaj P. Bullous fixed drug eruption (BFDE) following per-oral metronidazole. J Eur Acad Dermatol Venereol. 2003;17:607–09.

Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol. 2005;4(6):746–48.

Gupta S, Alam K, Palaian S, Singh M, Dwari B, Prabhu S, et al. Metronidazole Induced Bullous Fixed Drug Eruptions: A Case Report And A Review Of Literature. The Internet Journal of Dermatology. [Internet] 2006;5(1):1–5.

Bayer HealthCare AG (2011) Xarelto_(rivaroxaban) Summary of Product Characteristics as approved by the European Commission. Available: http://www.xarelto.com/html/downloads/Xalrelto_summary_of_product_characteristics.

J. Eduardo Calonje, MD, DipRCPath, Thomas Brenn, MD, PhD, FRCPath, Alexander J Lazar, MD, PhD and Phillip H. McKee, MD, FRCPath. McKee's Pathology of the Skin, 4rd ed Elsevier/Saunders, 2012.

Weedon, David, Geoffrey Strutton, and Adam I. Rubin. Weedon's skin pathology. 3rd ed. Edinburgh: Churchill Livingstone/Elsevier, 2010.

Hampton M. Vernon, BS, Andrew K. Nielsen, MD, Edward C. O' Bryan, MD. Case Report Hypersensitivity reaction after administration of rivaroxaban (Xarelto) Am J. Emerg Med 2016:1325.e1 1325.e2.

Yates J, Choudry M, Keys G. A case report describing a suspected rivaroxabano hypersensitivity reaction in a surgical patient. J Clin Pharm Ther 2013;38:159–61.

Published: 2018-01-15

Issue: Vol. 5 No. 3 (view)

Section: Articles

How to cite:
1.
Ferreira C, Oliveira A, Furtado A, Rocha N, Almeida Ribeiro J. Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study. EJCRIM 2018;5 doi:10.12890/2018_000724.